NRx Pharmaceuticals Launches Preservative-Free Ketamine

The Nasdaq-listed company has begun commercial sales of its newly FDA-approved ketamine injection, with shipments scheduled for January 2027.

Updated on Nov. 19, 2026 in Healthcare

NRx Pharmaceuticals Launches Preservative-Free Ketamine

NRx Pharmaceuticals has begun commercial sales operations for its preservative-free ketamine injection, which the FDA recently approved. The company deployed a 17-person national sales force this week and expects to begin product shipments in January 2027.

Why it matters

The launch is positioned as an alternative for hospitals seeking more predictable access to ketamine amid a longstanding U.S. drug shortage that began affecting the market in 2018. NRx's sales representatives have built relationships with purchasers and group purchasing organizations responsible for approximately 80% of U.S. ketamine sales.

The company's 17-person sales force is working to reach purchasers behind roughly 80% of U.S. ketamine sales, and it projects gross and net sales margins above 50%. Manufacturing costs under 20% of selling price for its blow-fill-seal process compare with 70% or more for traditional glass-vial production, though the margin projection remains unverified.

The players

NRx Pharmaceuticals

NRx Pharmaceuticals is a Wilmington, Delaware-based company listed on Nasdaq under the ticker NRXP that develops treatments targeting depression, post-traumatic stress disorder and suicidality.

The details

The injectable ketamine uses blow-fill-seal manufacturing, which forms, fills and seals a plastic vial in a single process, and is packaged in a preservative-free vial with a luer-lock connection that attaches directly to a sterile syringe. NRx also filed a citizen petition asking the FDA to remove benzethonium chloride from ketamine products and contracted German equipment suppliers to double its blow-fill-seal manufacturing footprint in South Carolina.

Timeline

  1. Ketamine injection supply shortages began affecting the market in 2018.

  2. NRx deployed its 17-person national sales force in November 2026.

  3. Initial supply agreements and preorders are expected before the end of 2026.

  4. Product shipments are scheduled to begin in January 2027.

Market Landscape

The launch enters a U.S. ketamine market shaped by supply shortages that have persisted since 2018, positioning NRx against incumbent suppliers by offering domestically manufactured product. Its sales force targets the hospital purchasers and group purchasing organizations that control most U.S. ketamine sales, a channel that determines which suppliers gain access to hospital formularies.

Hospitals and clinicians who rely on ketamine may see new supply options once shipments begin in January 2027, which the company positions as more predictable than current sources. Buyers should watch whether the company's product becomes available through their group purchasing channels, as availability will depend on contracts still to be finalized.

The takeaway

Persistent drug shortages leave hospitals with limited sourcing options, so new domestic manufacturers entering the market may gradually change how predictable ketamine supply becomes. Tracking announced supply agreements and actual shipment dates will show whether the launch delivers on its stated timeline.

What happens next

Initial supply agreements and preorders are expected before the end of 2026, and product shipments are scheduled to begin in January 2027.

Further reading

For broader context on pharmaceutical supply and hospital purchasing, see the Healthcare section.

Source note: This article includes information reported by MyChesCo.